Clinical trials: Nasopharyngeal Neoplasms
Head and Neck Neoplasms
NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)
Primary Objective: To estimate the overall response rate after neo-adjuvant chemotherapy of Docetaxel 75 mg/m2 in combination with Cisplatin 75 mg/m2 given for 3 cycles, and followed by conventional radiotherapy in UCNT.
- Trial name
- NCT00916097
- Testing
- DOCETAXEL(XRP6976)
- Where
- 3 sites in Algeria, Morocco and 1 more
- Volunteers
- 66 people
- Sponsor
- Sanofi